研究者情報

ハヤカワ　ノゾミ   HAYAKAWA NOZOMI   早川　望    所属   医学部医学科 腎泌尿器外科学    職種   講師
言語種別	日本語
発表タイトル	JAVEMACS chart review study of avelumab maintenance treatment (tx) in advanced urothelial carcinoma (aUC) in Japan: analyses in older patients (pts)
会議名	第112回日本泌尿器科学会総会
学会区分	全国規模の学会
発表形式	口頭
講演区分	一般
発表者・共同発表者	Shirotake Suguru, Kitamura Hiroshi, Nakagawa Tohru, Murakami Kaoru, Ikarashi Daiki, Naito Sei, Hayakawa Nozomi, Miura Noriyoshi, Yatsuda Junji, Nishiyama Naotaka, Shono Michihiro, Kobayashi Takashi, Kikuchi Eiji
発表年月日	2025/04/18
開催地 （都市, 国名）	福岡県福岡市
開催期間	2025/04/17～2025/04/19
概要	[Object] Avelumab maintenance tx is approved in Japan for pts with curatively unresectable UC not progressed after platinum-based chemotherapy (PBC). Older pts often have greater comorbidity but are underrepresented in clinical trials; thus treatment sequencing is a key consideration. We report data for older subgroups from a chart review study of avelumab maintenance tx in Japan. [Methods] In this multicenter retrospective study, medical charts of pts with aUC who started avelumab maintenance tx after first-line (1L) PBC between Feb 2021 and Dec 2023 were reviewed. [Results] Of 354 pts, 41.2% were aged ≧75 y and 16.7% were ≧80 y. In ≧75/≧80 y subgroups, ECOG performance status was 0 in 71.9%/64.4%, 1 in 23.3%/28.8%, and ≧2 in 3.4%/6.8%; primary tumor location was bladder in 50.0%/44.1% and renal pelvis or ureter in 47.9%/54.2%; 15.6%/15.1% were cisplatin eligible, 58.9%/56.6% cisplatin ineligible/platinum eligible, and 19.1%/24.5% platinum ineligible; 1L PBC regimen was gemcitabine (G) + cisplatin in 49.6%/39.6% and G + carboplatin in 42.6%/49.1%; and no. of PBC cycles was 1-3 in 25.5%/26.4%, 4 in 58.2%/54.7%, 5/6 in 14.9%/17.0%, and ≧7 in 1.4%/1.9%. In ≧75/≧80 y subgroups, median overall survival (OS; 95% CI) from start of avelumab was not estimable (NE; 24.3-NE)/25.0 (17.5-NE) mo. Second-line tx was received by 50.4%/39.6% (enfortumab vedotin in 70.4%/66.7%, PBC in 18.3%/14.3%, pembrolizumab in 8.5%/14.3%). [Conclusions] In this descriptive analysis of real-world data from pts with aUC in Japan, OS in older subgroups was comparable to prior data from the total population.